Sirukumab (CNTO 136; Janssen/GlaxoSmithKline) is a human monoclonal antibody interleukin-6 receptor antagonist that is currently in Phase III development for rheumatoid arthritis. Sirukumab is also being investigated as a potential treatment for lupus nephritis.
To date, sirukumab’s (Johnson & Johnson/GlaxoSmithKline) clinical performance has been comparable to that of the first-to-market interleukin (IL)-6 inhibitor Actemra (tocilizumab; Chugai/Roche) and the Phase III candidate sarilumab (Sanofi/Regeneron). Datamonitor Healthcare believes that this lack of differentiation, together with sirukumab’s anticipated late market entry in Q2 2018, will restrict the drug’s patient share, even in light of Janssen’s extensive experience in autoimmune indications. Once approved and launched, sirukumab is expected to be used late in the rheumatoid arthritis (RA) treatment paradigm, targeting non-responders to tumor necrosis factor (TNF) therapy.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 sirukumab : Rheumatoid arthritis
LIST OF FIGURES
7 Figure 1: Sirukumab Phase IIa trial design
8 Figure 2: Sirukumab SWOT analysis in rheumatoid arthritis
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of sirukumab (Johnson &
Johnson/GlaxoSmithKline) for rheumatoid arthritis
10 Figure 4: Datamonitor Healthcare’s drug assessment scores and weightings of sirukumab
(Johnson & Johnson/GlaxoSmithKline) for rheumatoid arthritis
LIST OF TABLES
4 Table 1: Sirukumab (Johnson & Johnson/GlaxoSmithKline) drug profile
5 Table 2: Sirukumab’s Phase III trials in rheumatoid arthritis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.